The Southwest Oncology Group (SWOG) 1416 phase II trial was designed to compare the efficacy of the PARP inhibitor veliparib plus cisplatin versus cisplatin alone in patients with metastatic and/or locally recurrent triple-negative breast cancer (TNBC) or *BRCA1* or *BRCA2* germline mutation–associated HER2-negative metastatic breast cancer. Priyanka Sharma, MD, of the University of Kansas Medical Center, presented the results of this trial during the ASCO20 Virtual Scientific Program .
Eligible patients were randomly assigned 1:1 to receive either treatment with cisplatin 75 mg/m2 on day 1 combined with veliparib 300 mg orally twice daily (BID) on days 1 to 14 (21-day cycle) or cisplatin 75 mg/m2 on day 1 plus placebo BID on days 1 to 14 (21-day cycle). Dr. Sharma noted that the veliparib 300 mg BID dose in this trial is much higher than that used in other studies such as BROCADE 3 .
After being randomly assigned, all pa...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Combination pembrolizumab/chemo improves PFS in metastatic TNBC Next Article
Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.